Citicoline per Attention & Focus Difficulties

B Evidenze Almeno un trial randomizzato lo supporta, con risultati per lo più coerenti.

Researchers reviewing 14 studies found established evidence for improvements in attention, processing speed, and working memory with citicoline supplementation, particularly in elderly populations with existing cognitive complaints.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dciticoline\u0026condition\u003Dattention\u002Dfocus'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

In sintesi

Key Study Findings

Randomized Controlled Trial Double-blind

Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study.

Dose: None vs: placebo Outcome: ADHD symptom improvement Effetto: None None

Popolazione: pediatric patients aged 7-12 years diagnosed with ADHD

Other 12 weeks

Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome.

Dose: 19.17% vs: None Outcome: cognitive function Effetto: None None

Popolazione: Covid-19 during the pandemic period between 2020 and 2022

Systematic Review n=8137

Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review.

Dose: None vs: None Outcome: Cocaine craving reduction Effetto: None None

Popolazione: Cocaine use disorder patients

Review

Cholinergic nervous system and glaucoma: From basic science to clinical applications.

Dose: None vs: None Outcome: Mortality Effetto: None None

Popolazione: None

Review

[X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion].

Dose: None vs: None Outcome: None Effetto: None None

Popolazione: None

Key Statistics

Studi

1600

Partecipanti

↑

Positive

Grado

Referenced Papers

Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study. RCT

Clinical neuropharmacology None 2 citazioni

Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome. Other

Diagnostics (Basel, Switzerland) 2023

Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. Review

Brain sciences 2022 17 citazioni

Cholinergic nervous system and glaucoma: From basic science to clinical applications. Review

Progress in retinal … 2019 107 citazioni

[X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion]. Review

Revista de neurologia 2012 12 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:: 250-500 mg/day
cognitivesupport:: 500-2,000 mg/day

Limite massimo: Well-tolerated up to 4,000 mg/day in clinical trials

Dosaggi studiati nella ricerca

Dosaggio	Durata	Effetto	N
None	--	Neutral	--
19.17%	12 weeks	Positive	--
None	--	Mixed	8137
None	--	Positive	--
None	--	Mixed	--

Momento migliore per l'assunzione: Morning or split dose; can be taken with or without food

Safety & Side Effects

Effetti collaterali segnalati

⚠ Headache
⚠ Insomnia (if taken late in the day)
⚠ Mild gastrointestinal discomfort
⚠ Rare: restlessness or overstimulation

Interazioni note

● Levodopa (may enhance dopaminergic effects)
● Cholinergic drugs (additive acetylcholine increase)
● Anticholinergics (may reduce citicoline effectiveness)

Livello di assunzione massimo tollerabile: Well-tolerated up to 4,000 mg/day in clinical trials

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Citicoline help with Attention & Focus Difficulties?

Based on 14 studies with 1,600 participants, there is moderate evidence from clinical studies that Citicoline may support Attention & Focus Difficulties management. Our evidence grade is B (Good Evidence).

How much Citicoline should I take for Attention & Focus Difficulties?

Studies have used various dosages. A commonly studied range is 250-500 mg/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Citicoline?

Reported side effects may include Headache, Insomnia (if taken late in the day), Mild gastrointestinal discomfort, Rare: restlessness or overstimulation. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Citicoline and Attention & Focus Difficulties?

We rate the evidence as Grade B (Good Evidence). This rating is based on 14 peer-reviewed studies with 1,600 total participants. The overall direction of effect is positive.

Altri ingredienti per Attention & Focus Difficulties

L-Theanine B Omega-3 Fatty Acids (DHA/EPA) C Bacopa monnieri C Phosphatidylserine C

Citicoline per altre condizioni

Memory Loss B

Verdetto rapido

Evidence Strength72%

High confidence

Analisi degli studi

RCT (1)Meta (0)Other (13)

Confronta le alternative

Scoprite come si confrontano altri ingredienti per questa condizione.

Visualizza tutti gli ingredienti per Attention & Focus Difficulties

Approfondimenti

References

[1] Isabel Barros Hübner et al.. Clin Neuropharmacol. Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study. doi:10.1097/WNF.0000000000000602 PubMed
[2] Milena Dimitrova et al.. Diagnostics (Basel). 2023. Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome. doi:10.3390/diagnostics13162703 PubMed
[3] Dângela Layne Silva Lassi et al.. Brain Sci. 2022. Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. doi:10.3390/brainsci12111546 PubMed
[4] Muneeb A Faiq et al.. Prog Retin Eye Res. 2019. Cholinergic nervous system and glaucoma: From basic science to clinical applications. doi:10.1016/j.preteyeres.2019.06.003 PubMed
[5] M Carmen Carrascosa-Romero et al.. Rev Neurol. 2012. [X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion]. PubMed

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.